Jerusalem factory for Universal Flu vaccine
Israeli biotech Biondvax is to receive a Government grant for 20% of the NIS 20 million required to build a Jerusalem factory for commercial scale production of its M-001 Universal Flu vaccine. Biondvax plans to produce tens of millions of doses of M-001 annually, including for Phase 3 trials.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink